Demographic, clinical, and cytogenetic features of 349 adults with ALL
| . | Age, y . | Total . | ||
|---|---|---|---|---|
| 15 to 29 . | 30 to 59 . | 60 or older . | ||
| No. of patients | 115 | 110 | 124 | 349 |
| Sex ratio, M:F | 1:0.6 | 1:1.1 | 1:1.1 | 1:0.9 |
| WCC × 109/L, n (%)* | ||||
| < 10 | 55 (48) | 40 (38) | 42 (41) | 137 (43) |
| 10-49.9 | 35 (30) | 33 (32) | 46 (45) | 114 (36) |
| ≥ 50 | 24 (21) | 31 (30) | 14 (14) | 69 (21) |
| Immunophenotype, n (%)† | ||||
| Pro-B | 7 (7) | 15 (15) | 11 (12) | 33 (10) |
| B-cell precursor | 71 (68) | 60 (59) | 44 (49) | 175 (55) |
| Mature B | 1 (< 1) | 10 (10) | 21 (23) | 32 (10) |
| T-ALL | 26 (25) | 11 (11) | 5 (6) | 42 (13) |
| Biphenotypic | 0 | 6 (6) | 9 (10) | 15 (5) |
| Cytogenetic investigations | ||||
| Attempted | 98 (85) | 100 (91) | 94 (73) | 292 (84) |
| Successful | 77 (79) | 79 (79) | 80 (85) | 236 (81) |
| Normal | 25 (32) | 19 (24) | 18 (23) | 62 (26) |
| Abnormal | 52 (68) | 60 (76) | 62 (77) | 174 (74) |
| Cytogenetic investigations before January 1993, n (%) | ||||
| Attempted | 44 (76) | 51 (86) | 37 (61) | 132 (74) |
| Successful | 32 (73) | 38 (75) | 30 (81) | 100 (76) |
| Normal | 12 (38) | 8 (21) | 11 (37) | 31 (31) |
| Abnormal | 20 (63) | 30 (79) | 19 (63) | 69 (69) |
| Cytogenetic investigations after January 1993, n (%) | ||||
| Attempted | 54 (95) | 49 (96) | 57 (90) | 160 (94) |
| Successful | 45 (88) | 41 (84) | 50 (88) | 136 (85) |
| Normal | 13 (29) | 11 (27) | 7 (14) | 31 (23) |
| Abnormal | 32 (71) | 30 (73) | 43 (86) | 105 (77) |
| Chromosomal abnormality, n (%)‡ | ||||
| Total | 77 | 79 | 80 | 236 |
| t(9;22)(q34;q11) | 6 (8) | 16 (20) | 14 (18) | 36 (15) |
| t(4;11)(q21;q23) | 4 (5) | 5 (6) | 1 (1) | 10 (4) |
| t(1;19)(q23;p13) | 4 (5) | 2 (3) | 0 | 6 (3) |
| t(8;14)(q24;q32) | 0 | 7 (9) | 10 (13) | 17 (7) |
| t(14;18)(q32;q21)§ | 0 | 2 (3) | 8 (10) | 10 (4) |
| HeH‖ | 10 (13) | 4 (5) | 3 (4) | 17 (7) |
| HoTr¶ | 1 (1) | 2 (3) | 4 (5) | 7 (3) |
| Complex# | 2 (3) | 4 (6) | 9 (11) | 15 (7) |
| Other | 25 (32) | 18 (23) | 16 (20) | 59 (25) |
| Normal** | 25 (32) | 19 (24) | 18 (23) | 62 (26) |
| CR rate, % (n)†† | 89 (99/111) | 77 (75/97) | 51 (20/39) | 79 (194/247) |
| OS estimate, 5 y (95% confidence interval), %‡‡ | 45 (35-55) | 19 (11-28) | 12 (4-27) | 30 (24-36) |
| . | Age, y . | Total . | ||
|---|---|---|---|---|
| 15 to 29 . | 30 to 59 . | 60 or older . | ||
| No. of patients | 115 | 110 | 124 | 349 |
| Sex ratio, M:F | 1:0.6 | 1:1.1 | 1:1.1 | 1:0.9 |
| WCC × 109/L, n (%)* | ||||
| < 10 | 55 (48) | 40 (38) | 42 (41) | 137 (43) |
| 10-49.9 | 35 (30) | 33 (32) | 46 (45) | 114 (36) |
| ≥ 50 | 24 (21) | 31 (30) | 14 (14) | 69 (21) |
| Immunophenotype, n (%)† | ||||
| Pro-B | 7 (7) | 15 (15) | 11 (12) | 33 (10) |
| B-cell precursor | 71 (68) | 60 (59) | 44 (49) | 175 (55) |
| Mature B | 1 (< 1) | 10 (10) | 21 (23) | 32 (10) |
| T-ALL | 26 (25) | 11 (11) | 5 (6) | 42 (13) |
| Biphenotypic | 0 | 6 (6) | 9 (10) | 15 (5) |
| Cytogenetic investigations | ||||
| Attempted | 98 (85) | 100 (91) | 94 (73) | 292 (84) |
| Successful | 77 (79) | 79 (79) | 80 (85) | 236 (81) |
| Normal | 25 (32) | 19 (24) | 18 (23) | 62 (26) |
| Abnormal | 52 (68) | 60 (76) | 62 (77) | 174 (74) |
| Cytogenetic investigations before January 1993, n (%) | ||||
| Attempted | 44 (76) | 51 (86) | 37 (61) | 132 (74) |
| Successful | 32 (73) | 38 (75) | 30 (81) | 100 (76) |
| Normal | 12 (38) | 8 (21) | 11 (37) | 31 (31) |
| Abnormal | 20 (63) | 30 (79) | 19 (63) | 69 (69) |
| Cytogenetic investigations after January 1993, n (%) | ||||
| Attempted | 54 (95) | 49 (96) | 57 (90) | 160 (94) |
| Successful | 45 (88) | 41 (84) | 50 (88) | 136 (85) |
| Normal | 13 (29) | 11 (27) | 7 (14) | 31 (23) |
| Abnormal | 32 (71) | 30 (73) | 43 (86) | 105 (77) |
| Chromosomal abnormality, n (%)‡ | ||||
| Total | 77 | 79 | 80 | 236 |
| t(9;22)(q34;q11) | 6 (8) | 16 (20) | 14 (18) | 36 (15) |
| t(4;11)(q21;q23) | 4 (5) | 5 (6) | 1 (1) | 10 (4) |
| t(1;19)(q23;p13) | 4 (5) | 2 (3) | 0 | 6 (3) |
| t(8;14)(q24;q32) | 0 | 7 (9) | 10 (13) | 17 (7) |
| t(14;18)(q32;q21)§ | 0 | 2 (3) | 8 (10) | 10 (4) |
| HeH‖ | 10 (13) | 4 (5) | 3 (4) | 17 (7) |
| HoTr¶ | 1 (1) | 2 (3) | 4 (5) | 7 (3) |
| Complex# | 2 (3) | 4 (6) | 9 (11) | 15 (7) |
| Other | 25 (32) | 18 (23) | 16 (20) | 59 (25) |
| Normal** | 25 (32) | 19 (24) | 18 (23) | 62 (26) |
| CR rate, % (n)†† | 89 (99/111) | 77 (75/97) | 51 (20/39) | 79 (194/247) |
| OS estimate, 5 y (95% confidence interval), %‡‡ | 45 (35-55) | 19 (11-28) | 12 (4-27) | 30 (24-36) |
ALL indicates acute lymphoblastic leukemia; CR, complete remission; HeH, high hyperdiploidy; HoTr, low hypodiploidy/near triploidy; OS, overall survival; T-ALL, T-lineage acute lymphoblastic leukemia; and WCC, white cell count.
Information only available for 320 patients.
Information only available for 297 patients.
Mutually exclusive.
This chromosomal abnormality was expressed in conjunction with the t(8;14) in 3 patients.
High hyperdiploidy (51-65 chromosomes).
Low hyperdiploidy (30-39 chromosomes)/near triploidy (60-78 chromosomes).
Complex karyotype defined as 5 or more chromosomal abnormalities in the absence of an established cytogenetic subgroup.
A total of 20 or more normal metaphases in the absence of any clonal chromosomal abnormality.
CR only available for 247 patients.
OS rate available for 234 patients as the result of missing data.